Matches in Wikidata for { <http://www.wikidata.org/entity/Q83807176> ?p ?o ?g. }
Showing items 1 to 35 of
35
with 100 items per page.
- Q83807176 description "clinical trial" @default.
- Q83807176 description "ensayu clínicu" @default.
- Q83807176 description "klinisch onderzoek" @default.
- Q83807176 description "клінічне випробування" @default.
- Q83807176 name "Canakinumab and Azacitidine for the Treatment of Low or Intermediate Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia" @default.
- Q83807176 name "Canakinumab and Azacitidine for the Treatment of Low or Intermediate Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia" @default.
- Q83807176 type Item @default.
- Q83807176 label "Canakinumab and Azacitidine for the Treatment of Low or Intermediate Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia" @default.
- Q83807176 label "Canakinumab and Azacitidine for the Treatment of Low or Intermediate Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia" @default.
- Q83807176 prefLabel "Canakinumab and Azacitidine for the Treatment of Low or Intermediate Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia" @default.
- Q83807176 prefLabel "Canakinumab and Azacitidine for the Treatment of Low or Intermediate Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia" @default.
- Q83807176 P1050 Q83807176-4360E958-CF0D-4AD1-BC89-08F8FF7FA0DA @default.
- Q83807176 P1050 Q83807176-A714C2C9-CDDA-4247-978F-B93586B8D344 @default.
- Q83807176 P1132 Q83807176-F4702D23-CFF6-4BF3-8D5D-7A9074E55E6E @default.
- Q83807176 P1476 Q83807176-03736192-1DDE-4F58-8F88-5C1FCF610C14 @default.
- Q83807176 P17 Q83807176-7CBE2C86-0A16-4462-8422-D5BEE61FAAD2 @default.
- Q83807176 P2899 Q83807176-26BB43D8-150C-4616-A933-DA5832419D17 @default.
- Q83807176 P3098 Q83807176-0C3A09FF-EA47-416B-B65D-63EB58CAA3C5 @default.
- Q83807176 P31 Q83807176-84F7D493-8BB0-4587-8E3A-1DD4793A544F @default.
- Q83807176 P580 Q83807176-B0C27D8E-BE68-40D3-8AA6-4F334F808FC1 @default.
- Q83807176 P582 Q83807176-11B7168B-08EF-43B2-BCE3-56AE8EA237F2 @default.
- Q83807176 P6099 Q83807176-6F74BAB4-9674-4E4C-8531-CE10ED8B4ADC @default.
- Q83807176 P8363 Q83807176-B9B18277-914B-4557-993C-AB6D1EB89113 @default.
- Q83807176 P1050 Q179630 @default.
- Q83807176 P1050 Q29496 @default.
- Q83807176 P1132 "+60" @default.
- Q83807176 P1476 "Phase 2, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1B Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia" @default.
- Q83807176 P17 Q30 @default.
- Q83807176 P2899 "+18" @default.
- Q83807176 P3098 "NCT04239157" @default.
- Q83807176 P31 Q30612 @default.
- Q83807176 P580 "2020-06-01T00:00:00Z" @default.
- Q83807176 P582 "2022-01-31T00:00:00Z" @default.
- Q83807176 P6099 Q42824440 @default.
- Q83807176 P8363 Q78089383 @default.